Search company, investor...


Founded Year



Series B | Alive

Total Raised


Last Raised

$12M | 19 yrs ago

About Phylogix

Phylogix is an early-stage pharmaceutical company developing chemoprotectant compounds.

Headquarters Location

100 Beaver Street

Waltham, Massachusetts, 02453,

United States


Missing: Phylogix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Phylogix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Phylogix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Phylogix is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Phylogix Frequently Asked Questions (FAQ)

  • When was Phylogix founded?

    Phylogix was founded in 1998.

  • Where is Phylogix's headquarters?

    Phylogix's headquarters is located at 100 Beaver Street, Waltham.

  • What is Phylogix's latest funding round?

    Phylogix's latest funding round is Series B.

  • How much did Phylogix raise?

    Phylogix raised a total of $14.95M.

  • Who are the investors of Phylogix?

    Investors of Phylogix include Small Enterprise Growth Fund of Maine, BVF Partners, Radius Ventures, Atlas Venture, Canaan Partners and 3 more.

  • Who are Phylogix's competitors?

    Competitors of Phylogix include Numares, Annovis Bio, OcuCure Therapeutics, NeurOP, Santarus and 12 more.

Compare Phylogix to Competitors

ROXRO Pharma

Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Nimura Genetic Solutions

Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.

OcuCure Therapeutics

OcuCure Therapeutics is an ophthalmic pharmaceutical company developing new drugs. The company's lead compound has been formulated as a topical eye drop for both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD and DR are leading causes of blindness in developed countries. Additionally, the lead compound has potential for use as a prophylactic. The presence of the therapeutic target has been validated in human AMD and DR tissues. This confirms the OcuCure approach for treating ocular angiogensis. The topical eye drop also has demonstrated the ability to cross human corneas in in vitro studies. When the eye drop was administered to animals, the lead compound penetrated all the way back to the retina at clinically significant concentrations without any toxic effects observed. By comparison, the currently available drugs for AMD are administered by a monthly injection into the eye.


Neorphys is a specialty pharma company focusing on safe pain relief, especially visceral pain management.


MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.